22:04:04 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-13 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-23 Ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 Årsstämma 2024
2024-05-02 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-06-02 Årsstämma 2023
2023-06-02 Ordinarie utdelning VIMIAN 0.00 SEK
2023-05-04 Kvartalsrapport 2023-Q1
2023-03-24 Extra Bolagsstämma 2023
2023-03-08 Bokslutskommuniké 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-10-03 Extra Bolagsstämma 2022
2022-08-24 Kvartalsrapport 2022-Q2
2022-06-03 Ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 Årsstämma 2022
2022-05-24 Kvartalsrapport 2022-Q1
2022-03-09 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksamma inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.
2023-05-04 07:45:00

Positive start to the year

  • Revenue increased by 30 per cent to EUR 88.1m (67.9), of which 13 per cent was organic growth (16 per cent excluding Diagnostics)
  • Operating profit (EBIT) increased by 66 per cent to EUR 18.5m (11.2) at a margin of 21 per cent (16.4). Profit for the quarter totalled EUR 5.5m (5.5)
  • Adjusted EBITA increased by 27 per cent to EUR 26.1m (20.5) at a margin of 29.6 per cent (30.2) with items affecting comparability of EUR -2.6m (-4.8)

“Vimian had a positive start to the year with strong growth and profitability. Our efforts to accelerate organic growth proved successful and we delivered 13 per cent organic growth in the quarter. All segments are off to a positive start, and we look forward to continuing supporting veterinary clinics with new innovative products and services throughout the year”, says Dr. Fredrik Ullman, CEO of Vimian Group.

Last twelve months pro-forma revenues (including the full year impact of all acquisitions completed during the twelve months ending 31 March) reached EUR 320.6 million and pro-forma EBITA EUR 84.1 million.

“We successfully completed our annual ordering programme in MedTech, commercialised key innovation projects and continued to integrate acquired companies. We closed three strategically important acquisitions to strengthen our positions in Specialty Pharma and Veterinary Services”, says Dr. Fredrik Ullman, CEO of Vimian Group.

A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://conference.financialhearings.com/teleconference/?id=2001168

To attend the webcast:
Link: https://ir.financialhearings.com/vimian-group-q1-2023

Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.